Bioprocess Technology Market Shows Strong Momentum as Biologics Manufacturing Expands Worldwide
The bioprocess technology market has entered a period of strong expansion as pharmaceutical and biotechnology companies increase investment in biologics production, vaccine manufacturing, and the development of advanced therapeutics. The market has progressed from conventional batch-based stainless-steel systems to flexible, automated, and high-efficiency production platforms. Demand for high-purity biologics, biosimilars, and cell-based therapies has accelerated the adoption of modern upstream and downstream processing technologies. This transition continues to reshape manufacturing priorities and capital spending across global healthcare industries.
Industry expansion is supported by the rapid adoption of single-use systems, continuous manufacturing methods, advanced sensors, and digital control platforms. Companies are modernizing facilities to reduce contamination risk, improve scalability, and shorten production cycles. Contract development and manufacturing organizations are also expanding capacity, creating wider demand for bioreactors, filtration systems, and chromatography equipment. Increased use of data-driven production management further strengthens output reliability and cost control. Bioprocess technology market demand remains robust as producers seek faster and more efficient operations.
According to Value Market Research, the global demand for Bioprocess Technology market was valued at USD 40.91 Billion in 2025 and is expected to generate USD 87.96 Billion by 2034, growing at a CAGR of 8.58% between 2026 and 2034.
The major growth drivers include rising biologics approvals, expanding healthcare expenditure, and strong investment in personalized medicine. Regulatory standards for quality and traceability have encouraged automation and advanced monitoring across production lines. Companies are increasingly adopting high-yield cell culture systems and precision purification technologies to maximize batch performance. These trends continue to create strong revenue opportunities for equipment providers and service partners worldwide.
Future opportunities are emerging in the Asia-Pacific, Latin America, and the Middle East regions where domestic biomanufacturing capacity is increasing. Smaller biotech firms are outsourcing production, creating demand for flexible modular systems and scalable consumables. Sustainability goals also promote energy-efficient processes and waste-reduction strategies. Vendors that combine digital support, integrated systems, and lifecycle services are well placed to capture rising bioprocess technology market demand.
Bioprocess Technology Market Recent Developments
Jan 2026: AstraZeneca acquired Modella AI, a Boston-based artificial intelligence company, to enhance oncology research and drug development. The acquisition integrates Modella AI’s advanced data models and analytics into AstraZeneca’s R&D pipeline, supporting biomarker discovery and clinical development.
Feb 2026: Glatt Systems partnered with PreferCo to establish the “PreferCo-Glatt Centre of Excellence for Bioprocess Scale-Up” in Genome Valley, Hyderabad, India. The facility supports microbial precision fermentation with up to 1,500-liter bioreactor capacity and integrates AI-enabled process intelligence to accelerate lab-to-commercial scale transition.
Mar 2026: Samsung Biologics expanded its manufacturing footprint in the U.S. by acquiring a biologics manufacturing facility from GSK in Rockville, Maryland. This expansion strengthens large-scale bioprocessing capacity and supports growing demand for contract development and manufacturing (CDMO) services in biologics production.
Leading Market Players in the Bioprocess Technology Market
The bioprocess technology market reflects moderate to high concentration, with multinational life science companies holding a dominant share through broad portfolios and global service capabilities. Established participants account for nearly 60% of the competitive landscape. Emerging companies represent around 30%, driven by innovation in sensors, automation, and single-use systems. Niche specialists hold roughly 10%, serving custom filtration, analytics, and small-scale production needs. Leading players expand share through acquisitions, product launches, and regional manufacturing investments. Collaboration remains active among suppliers, biotech firms, CDMOs, and software providers to accelerate digital manufacturing adoption. Bioprocess technology market demand continues to support strategic partnerships and expansion initiatives.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a leading provider of bioprocess equipment, consumables, analytical instruments, and production support services. Its broad portfolio serves research laboratories and commercial biologics manufacturing sites. Strong geographic reach and recurring consumables demand help maintain leadership. The company remains highly active in expanding integrated solutions for biopharmaceutical producers worldwide.
Bio-Rad Laboratories
Bio-Rad Laboratories has a strong presence in life science tools and process analytics. Its offerings include chromatography media, laboratory instruments, quality testing systems, and purification technologies. The company supports productivity and compliance across bioprocess workflows. Continuous investment in research capabilities strengthens its role in modern biologics manufacturing environments globally.
Siemens Healthineers
Siemens Healthineers contributes through industrial automation, diagnostics, and digital process intelligence solutions. The company enables real-time monitoring, data integration, and predictive maintenance across production facilities. These capabilities help manufacturers improve efficiency and consistency. Its technology expertise supports the ongoing shift toward smart and connected bioprocess operations.
Danaher Corporation
Danaher Corporation holds a major position through its diversified life sciences businesses. The company supplies filtration, purification, genomic workflow, and production technologies used widely in biopharma facilities. Its acquisition-led strategy has strengthened portfolio depth. Strong operational systems and innovation investment continue to expand its global market influence.
Sartorius AG
Sartorius AG is recognized for expertise in single-use systems, filtration platforms, fluid management, and cell culture technologies. The company serves customers from early research through commercial production. Its close alignment with biologics manufacturers supports recurring demand. Strong innovation and customer support sustain its leadership position in the market.
Eppendorf SE
Eppendorf SE is well known for laboratory and pilot-scale bioprocess solutions. Its portfolio includes fermenters, bioreactors, mixers, and liquid handling systems used by research institutions and biotech firms. The company benefits from trusted engineering quality and reliable performance. It remains important in early-stage development and scale-up processes.
Lonza Group Ltd
Lonza Group Ltd combines bioprocess technology supply with contract manufacturing expertise. This dual position provides direct insight into production challenges and customer needs. The company offers media solutions, development support, and commercial manufacturing services. Strong exposure to cell therapy and biologics markets enhances long-term growth potential.
Nova Biomedical
Nova Biomedical specializes in analytical instruments for monitoring cell culture and production conditions. Its automated analyzers measure metabolites and process parameters with speed and precision. These systems help improve batch control and productivity. The company holds a valuable niche role within process analytics and manufacturing optimization.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. influences the market through large-scale biologics production, diagnostics leadership, and advanced pharmaceutical manufacturing capabilities. Internal manufacturing excellence drives adoption of modern process technologies. Its ongoing investment in biologics pipelines supports demand for high-performance bioprocess systems and related infrastructure globally.
Merck KGaA
Merck KGaA is a major supplier of filtration, purification, media preparation, and process development technologies. The company serves research and commercial manufacturing customers through integrated offerings. Strong technical expertise, innovation spending, and global operations help maintain a competitive leadership position within the expanding bioprocess technology sector.